Uric acid and inflammatory markers.

AIMS The role of uric acid (UA) in the process of atherosclerosis and atherotrombosis is controversial. Epidemiological studies have recently shown that UA may be a risk factor for cardiovascular diseases and a negative prognostic marker for mortality in subjects with pre-existing heart failure. METHODS AND RESULTS We evaluate a relationship between UA levels and several inflammatory markers in 957 subjects, free of severe renal failure, from a representative Italian cohort of persons aged 65-95. Plasma levels of UA and white blood cell (WBC) and neutrophil count, C-reactive protein, interleukin-1 receptor antagonist (IL-1ra), interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6r), interleukin-18 (IL-18), and tumor necrosis factor-alpha (TNF-alpha) were measured. Complete information on potential confounders was collected using standard methods. WBC (P=0.0001), neutrophils (P<0.0001), C-reactive protein (P<0.0001), IL-1ra (P<0.0001), IL-6 (P=0.0004), sIL-6r (P=0.002), IL-18 (P<0.0001), TNF-alpha (P=0.0008), and the percentage of subjects with abnormally high levels of C-reactive protein (P=0.004) and IL-6 (P=<0.0001) were significantly higher across UA quintiles. After adjustment for age, sex, behaviour- and disease-related confounders, results were virtually unchanged. In subjects with UA within the normal range, UA was significantly and independently associated with neutrophils count, C-reactive protein, IL-6, IL-1ra, IL-18, and TNF-alpha, whereas non-significant trends were observed for WBC (P=0.1) and sIL-6r (P=0.2). CONCLUSION A positive and significant association between UA and several inflammatory markers was found in a large population-based sample of older persons and in a sub-sample of participants with normal UA. Accordingly, the prevalence of abnormally high levels of C-reactive protein and IL-6 increased significantly across UA quintiles.

[1]  D. Galaris,et al.  Uric acid and oxidative stress. , 2005, Current pharmaceutical design.

[2]  M. Ichinose,et al.  Cytokine-mediated xanthine oxidase upregulation in chronic obstructive pulmonary disease's airways. , 2005, Pulmonary pharmacology & therapeutics.

[3]  Ildikó Kriszbacher,et al.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, New England Journal of Medicine.

[4]  L. Ferrucci,et al.  Vitamin E levels, cognitive impairment and dementia in older persons: the InCHIANTI study , 2005, Neurobiology of Aging.

[5]  M. Ochiai,et al.  Uric acid renal excretion and renal insufficiency in decompensated severe heart failure , 2005, European journal of heart failure.

[6]  S. Haffner,et al.  Inflammation and cardiovascular disease in patients with diabetes: lessons from the Diabetes Control and Complications Trial. , 2005, Circulation.

[7]  E. Block,et al.  Hyperuricemia induces endothelial dysfunction. , 2005, Kidney international.

[8]  R. Nagai,et al.  Association Between Serum Uric Acid, Metabolic Syndrome, and Carotid Atherosclerosis in Japanese Individuals , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[9]  G. Leoncini,et al.  Serum Uric Acid and Target Organ Damage in Primary Hypertension , 2005, Hypertension.

[10]  M. Hediger,et al.  Molecular physiology of urate transport. , 2005, Physiology.

[11]  S. Bandinelli,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC only. TRIALS The , 2004 .

[12]  Richard J. Johnson,et al.  A unifying pathway for essential hypertension. , 2005, American journal of hypertension.

[13]  G. Rosano,et al.  Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. , 2004, The American journal of cardiology.

[14]  P. Tessier,et al.  Monosodium urate monohydrate crystals induce the release of the proinflammatory protein S100A8/A9 from neutrophils , 2004, Journal of leukocyte biology.

[15]  L. Niskanen,et al.  Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. , 2004, Archives of internal medicine.

[16]  S. Jee,et al.  Serum uric acid and risk of death from cancer, cardiovascular disease or all causes in men , 2004, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[17]  J. Hare,et al.  Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications , 2004, The Journal of physiology.

[18]  S. Bandinelli,et al.  Impairments of Muscles and Nerves Associated with Peripheral Arterial Disease and Their Relationship with Lower Extremity Functioning: The InCHIANTI Study , 2004, Journal of the American Geriatrics Society.

[19]  D. Webb,et al.  Hyperuricaemia does not impair cardiovascular function in healthy adults , 2004, Heart.

[20]  K. Suzuki,et al.  Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers , 2002, European Journal of Epidemiology.

[21]  S. Marsoni,et al.  Molecular targeting: new therapeutic strategies to improve tumour apoptosis. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  D. Muzny,et al.  Two independent mutational events in the loss of urate oxidase during hominoid evolution , 2004, Journal of Molecular Evolution.

[23]  L. Chambless,et al.  Risk factors for progression to incident hyperinsulinemia: the Atherosclerosis Risk in Communities Study, 1987-1998. , 2003, American journal of epidemiology.

[24]  James E. Evans,et al.  Molecular identification of a danger signal that alerts the immune system to dying cells , 2003, Nature.

[25]  D. Webb,et al.  Uric acid reduces exercise-induced oxidative stress in healthy adults. , 2003, Clinical science.

[26]  M. Walters,et al.  Serum Urate as an Independent Predictor of Poor Outcome and Future Vascular Events After Acute Stroke , 2003, Stroke.

[27]  K. Tuttle,et al.  Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? , 2003, Hypertension.

[28]  Ping Li,et al.  Uric Acid Stimulates Monocyte Chemoattractant Protein‐1 Production in Vascular Smooth Muscle Cells Via Mitogen‐Activated Protein Kinase and Cyclooxygenase‐2 , 2003, Hypertension.

[29]  H. Ishizaka,et al.  Effect of Allopurinol Pretreatment on Free Radical Generation after Primary Coronary Angioplasty for Acute Myocardial Infarction , 2003, Journal of cardiovascular pharmacology.

[30]  P. Ponikowski,et al.  Uric Acid and Survival in Chronic Heart Failure: Validation and Application in Metabolic, Functional, and Hemodynamic Staging , 2003, Circulation.

[31]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[32]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[33]  T. Nakagawa,et al.  Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. , 2002, Hypertension.

[34]  A. Struthers,et al.  Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure , 2002, Circulation.

[35]  Rainer Hambrecht,et al.  Effects of Xanthine Oxidase Inhibition With Allopurinol on Endothelial Function and Peripheral Blood Flow in Hyperuricemic Patients With Chronic Heart Failure: Results From 2 Placebo-Controlled Studies , 2002, Circulation.

[36]  M. Alderman.  Uric acid and cardiovascular risk. , 2002, Current opinion in pharmacology.

[37]  I. Tkáč,et al.  Uric acid--a marker for systemic inflammatory response in patients with congestive heart failure? , 1912, Wiener klinische Wochenschrift.

[38]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[39]  D. Kass,et al.  Allopurinol Improves Myocardial Efficiency in Patients With Idiopathic Dilated Cardiomyopathy , 2001, Circulation.

[40]  W. Little,et al.  Allopurinol Enhances the Contractile Response to Dobutamine and Exercise in Dogs With Pacing-Induced Heart Failure , 2001, Circulation.

[41]  Luigi Ferrucci,et al.  Subsystems Contributing to the Decline in Ability to Walk: Bridging the Gap Between Epidemiology and Geriatric Practice in the InCHIANTI Study , 2000, Journal of the American Geriatrics Society.

[42]  H. Brenner,et al.  Association between C-reactive protein and features of the metabolic syndrome: a population-based study. , 2000, Diabetes care.

[43]  M. Pahor,et al.  Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP) , 2000, Journal of hypertension.

[44]  Jing Fang,et al.  Serum Uric Acid and Cardiovascular Mortality: The NHANES I Epidemiologic Follow-up Study, 1971-1992 , 2000 .

[45]  M. Alderman,et al.  Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. , 2000, JAMA.

[46]  F. Nieto,et al.  Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? , 2000, Atherosclerosis.

[47]  D. Kass,et al.  Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. , 1999, Circulation research.

[48]  Daniel Levy,et al.  Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study , 1999, Annals of Internal Medicine.

[49]  Luigi Ferrucci,et al.  Serum IL‐6 Level and the Development of Disability in Older Persons , 1999, Journal of the American Geriatrics Society.

[50]  Y. G. Kim,et al.  Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[51]  P. Poole‐Wilson,et al.  Uric acid in chronic heart failure: a marker of chronic inflammation. , 1998, European heart journal.

[52]  E. Marbán,et al.  Novel myofilament Ca2+-sensitizing property of xanthine oxidase inhibitors. , 1998, Circulation research.

[53]  S. Salvini.  A food composition database for epidemiological studies in Italy. , 1997, Cancer letters.

[54]  F Berrino,et al.  Relative validity and reproducibility of a food frequency dietary questionnaire for use in the Italian EPIC centres. , 1997, International journal of epidemiology.

[55]  J. Damen,et al.  Reduction of reperfusion injury of human myocardium by allopurinol: a clinical study. , 1995, Free radical biology & medicine.

[56]  R. Goldberg,et al.  Lifestyle and biologic factors associated with atherosclerotic disease in middle-aged men. 20-year findings from the Honolulu Heart Program. , 1995, Archives of internal medicine.

[57]  T. Byers,et al.  Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. , 1995, American journal of epidemiology.

[58]  Linda P. Fried,et al.  The Women's Health and Aging Study: Health and Social Characteristics of Older Women with Disability , 1995 .

[59]  A. Dyer,et al.  Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. , 1989, Journal of clinical epidemiology.

[60]  M. Blaufox,et al.  Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. , 1987, Archives of internal medicine.

[61]  G. Oyeyinka.  Age and sex differences in immunocompetence. , 1984, Gerontology.

[62]  B. Ames,et al.  Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[63]  J. Wyngaarden,et al.  Gout and hyperuricemia , 1976 .